Abstract: [Abstract]Objective： To observe the clinical effect of gleevec on Ph acute lymphoblastic leukaemia（Ph ALL） cases in children.Methods： 9 cases of children Ph ALL were retrospectively analyzed. All of the data were obtained from department of hematology/oncology， in our hospital from January 2011 to May 2014.All the patients were treated with 340 mg/m2·d of oral gleevec in 0.5 h after meals， 30d for a course of treatment meanwhile， observed the genetics remission rate and recorded the occurrence of side effects treated with gleevec. Results： 9 cases(100%) were achieved complete genetic remission.With median follow-up time for 18 months， 9 cases of survival rate of Ph ALL patients was 67% in 2~4 years. Of the patients， 2 cases of recurrence after 13 months gave up treatment.1 case was treated for allogeneic hematopoietic stem cell transplantation after recurrence.Different levels of hypocytosis occured after 16 weeks (medium time was approximately 3~4 weeks).Including animia 7 cases(78%)， thrombocytopenia 5 cases(56%)， leukocytopenia 6 cases(67%)， pancytopenia 3 cases(33%). Nausea and vomiting occurred in 4 cases(44%) and muscle pain occurred in 2 cases(22%) which returned to normal after discontinuation or reduction. Conclusion：Gleevec is both effective and safe for the treatment of Ph ALL.